83-5980-59　VEGF, Bevacizumab Biosimilar 100ug　052006

特徴

• Bevacizumab is a humanized IgG1 kappa monoclonal antibody that selectively binds with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 protein, HER2.
• Bevacizumab is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary).
• Applications:Suitable for use in Functional Assays.
• Other applications not tested.
• Recommended Dilution:Optimal dilutions to be determined by the researcher.
• Storage and Stability:May be stored at 4℃ for short-term only.
• Aliquot to avoid repeated freezing and thawing.
• Store at -20℃.
• Aliquots are stable for 12 months after receipt.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

仕様

• Size：100ug
• 抗体種類：Mab
• 宿主：human
• Source Antibody：human
• Grade：Affinity Purified
• Purity：Purified by Protein A/G affinity chromatography. Endotoxin: ≤0.75EU/mg (LAL)
• Form：Supplied as a sterile, clear or slightly milky white, colorless to light brown liquid, containing trehalose, monobasic sodium phosphate monohydrate, sodium dihydrogen phosphate and Tween 20. pH 6.2. BSA and Azide free.
• Specificity：Recognizes human VEGF. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Bevacizumab.
• Isotype：IgG1
• Calc Crossreactivity：Hu
• Immunogen：Recombinant protein corresponding to human VEGF, expressed in CHO cells.
• この商品は法規制を確認しておりません。(法規制によって販売できない場合もございます)
• 製品の仕様は予告なく変更になる場合がございます。最新仕様はメーカーホームページをご確認ください。

• 【試薬に関するお問合せ】
• アズワン株式会社 試薬・プロセス材料グループ
• TEL：06-6447-8641
• FAX：06-6447-8642
• E-mail：[email protected]